You just read:

Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung

News provided by

Oncolytics Biotech Inc.

Feb 08, 2013, 06:30 EST